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Abstract
Mesolimbic dopamine (DA) is involved in behavioral activation and effort-related processes. Rats with impaired DA
transmission reallocate their instrumental behavior away from food-reinforced tasks with high response requirements, and
instead select less effortful food-seeking behaviors. In the present study, the effects of several drug treatments were
assessed using a progressive ratio (PROG)/chow feeding concurrent choice task. With this task, rats can lever press on a
PROG schedule reinforced by a preferred high-carbohydrate food pellet, or alternatively approach and consume the less-
preferred but concurrently available laboratory chow. Rats pass through each ratio level 15 times, after which the ratio
requirement is incremented by one additional response. The DA D2 antagonist haloperidol (0.025–0.1 mg/kg) reduced
number of lever presses and highest ratio achieved but did not reduce chow intake. In contrast, the adenosine A2A
antagonist MSX-3 increased lever presses and highest ratio achieved, but decreased chow consumption. The cannabinoid
CB1 inverse agonist and putative appetite suppressant AM251 decreased lever presses, highest ratio achieved, and chow
intake; this effect was similar to that produced by pre-feeding. Furthermore, DA-related signal transduction activity
(pDARPP-32(Thr34) expression) was greater in nucleus accumbens core of high responders (rats with high lever pressing
output) compared to low responders. Thus, the effects of DA antagonism differed greatly from those produced by pre-
feeding or reduced CB1 transmission, and it appears unlikely that haloperidol reduces PROG responding because of a
general reduction in primary food motivation or the unconditioned reinforcing properties of food. Furthermore, accumbens
core signal transduction activity is related to individual differences in work output.
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Introduction
Brain dopamine (DA), particularly in nucleus accumbens, plays
an important role in regulating aspects of instrumental behavior
[1–4]. Accumbens DA is involved in approach behavior,
activational aspects of motivation (e.g. vigor, persistence), and
enabling organisms to overcome work-related response costs to
gain access to significant stimuli [1–13]. The increased activity
induced by scheduled presentation of food pellets is accompanied
by increases in accumbens DA release, and is reduced by DA
antagonism and accumbens DA depletions [5,14]. Rats with
accumbens DA depletions are very sensitive to ratio requirements
in operant schedules [15–17]. Moreover, DA antagonism or
interference with accumbens DA transmission alters response
allocation in tasks that measure effort-related choice behavior
[1,2,6,7].
Several behavioral tasks have been used to investigate the role of
DA in effort-related choice. Some studies have used a T-maze
barrier choice task, and reported that interference with DA
transmission decreased barrier climbing to gain access to a high
magnitude of reinforcement [12,18–22]. T-maze and lever
pressing versions of effort discounting procedures also have
demonstrated that DA antagonism shifts choice behavior of rats
towards low effort alternatives [23,24]. Another task that has been
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used is the concurrent fixed-ratio 5 (FR5)/chow feeding proce-
dure, in which rats can either lever press on a FR5 schedule for
preferred high-carbohydrate food pellets, or approach and
consume less-preferred rodent chow that is freely available in
the chamber [1,6,25]. Under baseline conditions, rats tested with
this procedure typically obtain most of their food by lever pressing
while consuming very little of the chow. Systemic or intra-
accumbens administration of DA antagonists and accumbens DA
depletions shift response allocation such that lever pressing is
decreased but chow intake is substantially increased [6,25–31].
This effect is not due to drug-induced changes in food preference
or consumption [6,28]. Moreover, the effects induced by DA
antagonism or depletion differ substantially from those seen
following pre-feeding [6] or treatment with appetite suppressant
drugs such as fenfluramine [25] or cannabinoid CB1 antagonism
[30]; these appetite-related manipulations failed to increase chow
intake at doses that suppress lever pressing.
In addition to accumbens DA, there is a body of research
implicating adenosine in behavioral activation and effort-related
processes [32-34]. Adenosine A2A receptors are primarily localized
in striatal areas, including both neostriatum and accumbens
[35,36]. Furthermore, there is a functional interaction between
DA D2 and adenosine A2A receptors [37–39]. Intra-accumbens
injections of the adenosine A2A agonist CGS 21680 decreased
lever pressing on a ratio schedule [34], and also produced changes
in effort-related choice behavior similar to the effects of DA
antagonism [33]. In contrast, adenosine A2A antagonists have been
shown to increase fixed interval response rate [40]. Furthermore,
several studies have shown that adenosine A2A antagonists can
reverse the effects of DA D2 antagonists on tests of effort-related
choice behavior [21,22,31,32,41,42].
The present studies employed a variant of the lever pressing/
chow intake choice procedure, which utilized a progressive ratio
(PROG) work requirement (see also refs. [13,43]). Similar to the
FR5/chow feeding choice task, rats tested with this PROG/chow
feeding procedure have the choice of pressing the lever reinforced
by presentation of the more preferred pellets vs. approaching and
consuming the less preferred chow; the difference is that a PROG
schedule, which gradually increases the ratio requirement, is used
instead of an FR5. This variant of the choice procedure was used
because the PROG schedule requires that the animal repeatedly
make within-session choices between lever pressing and chow
intake under conditions in which the ratio requirement was
gradually incrementing. Moreover, preliminary data indicated
that the PROG/chow feeding choice procedure generates much
more variability in behavior between animals than the FR5 choice
procedure, which could be particularly useful for studying
neurochemical correlates of individual differences in behavior.
To assess the effects of DA antagonism and compare these actions
with other conditions, experiments were conducted to determine
the effects of the DA D2 antagonist haloperidol, the adenosine A2A
antagonist MSX-3, the cannabinoid CB1 antagonist/inverse
agonist and putative appetite suppressant AM251, and the
reinforcer devaluation provided by pre-feeding. Furthermore, to
investigate signal transduction activity that is potentially related to
task performance, expression of DARPP-32 that is phosphorylated
at the threonine 34 residue (pDARPP-32-(Thr34) [44] was
measured immunohistochemically in 4 specific regions of interest.
pDARPP-32(Thr34) immunoreactivity was used to provide a
marker of DA-related signal transduction activity, because
evidence indicates that DA acting through the D1 receptor and
the G proteins Gs/Golf activates adenylate cyclase activity, thereby
stimulating PKA-mediated phosphorylation of DARPP-32 at the
Thr34 site [45,46,47,48]. This experiment was conducted to
determine if levels of pDARPP-32(Thr34) expression were higher
in animals with high lever pressing output. Nucleus accumbens is
implicated in effort-related processes, so both the core and shell
divisions were analyzed for pDARPP-32(Thr34) activity following
a PROG/Choice behavioral session. Because Schweimer and
Hauber [43] demonstrated the importance of DA signaling in the
anterior cingulate cortex in effort-related decision making, CG1
and CG2 divisions of the cingulate cortex also were analyzed.
It was hypothesized that haloperidol would affect PROG
responding in a manner that was not dependent upon decreases in
primary food motivation or appetite, and thus would decrease
PROG lever pressing but leave chow intake intact. Moreover, it
was hypothesized that MSX-3 would produce behavioral effects
that would be opposite to those produced by haloperidol. Due to
the putative appetite suppressant effects of interfering with
cannabinoid CB1 receptor transmission [1,30,49,50], it was
expected that AM251, as well as pre-feeding, would decrease
both lever pressing and chow consumption. Finally, it was
hypothesized that accumbens DARPP-32 immunoreactivity would
be greater in animals with high baseline levels of lever pressing
(i.e., ‘‘high responders’’) than in rats with low levels of lever
pressing.
Materials and Methods
Animals
48 adult male Sprague-Dawley rats (Harlan, Indianapolis, IN,
USA) were housed in a colony at 23uC with 12-h light/dark cycles
(lights on at 0:700 h). Rats weighed 300–350 g at the beginning of
the study, and were initially food deprived to 85% of their free-
feeding body weight for training. Rats were fed supplemental chow
to maintain weight throughout the study, with water available ad
libitum in the home cages. Despite food restriction, rats were
allowed modest weight gain throughout the experiment. All
animal protocols were approved by the University of Connecticut
Institutional Animal Care and Use Committee, and followed NIH
guidelines.
Pharmacological Agents and Dose Selection
Haloperidol was obtained from Sigma-Aldrich (St. Louis, MO)
and was dissolved in 0.2% tartaric acid solution. MSX-3 ((E)-
phosphoric acid mono-[3-[8-[2-(3-methoxyphenyl)vinyl]-7-meth-
yl-2,6-dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl] propyl]
ester disodium salt) was synthesized in the laboratory of Christa
Mu¨ller (University of Bonn, Bonn, Germany). MSX-3 was
dissolved in 0.9% saline and pH adjusted with 1.0 M NaOH to
a final pH of 7.4. AM251 was synthesized in the laboratory of Alex
Makriyannis (Center for Drug Discovery, Northeastern University,
Boston, MA). AM251 was dissolved in dimethylsulfoxide (DMSO),
Tween 80, and 0.9% saline at a ratio of 1:1:8. Doses were selected
based on previous work [30,40,41].
Behavioral Procedures
Preliminary studies were conducted to determine the optimal
rate at which the schedule progressed (i.e., number of reinforce-
ments per ratio level and by how much the ratio requirement
increased with each level). It was found that by having to complete
15 ratios at each ratio level, rats generally lever pressed at higher
levels before switching to chow. Behavioral sessions were
conducted in operant conditioning chambers (28623623 cm3;
Med Associates). Rats were initially trained to lever press on a
continuous reinforcement schedule (30-min sessions; 45-mg high
carbohydrate pellets, Bio-serv, Frenchtown, NJ, USA) for 1 week,
and then were shifted to the PROG schedule (30-min sessions, 5
Dopamine Effort Progressive Ratio DARPP-32
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days/week) for several additional weeks. For PROG sessions, the
ratio started at FR1 and was increased by one additional response
every time 15 reinforcements were obtained (FR1615, FR2615,
FR3615,…). Additionally, this schedule included a ‘‘time-out’’
feature that deactivated the response lever if 2 minutes elapsed
without a ratio being completed. Upon reaching stable baseline
responding, chow was then introduced. Weighed amounts of
laboratory chow (Laboratory Diet, 5P00 Prolab RMH 3000,
Purina Mills, St. Louis, MO, USA; typically 15–20 g) were
concurrently available on the floor of the chamber during the
PROG sessions. At the end of the session, rats were removed from
the chamber, and food intake was determined by weighing the
remaining food (including spillage). Rats were trained until they
attained stable levels of baseline lever pressing and chow intake,
after which drug testing began. For most baseline days rats did not
receive supplemental feeding, however, over weekends and after
drug tests, rats received supplemental chow in the home cage. On
baseline and drug treatment days, rats normally consumed all the
operant pellets that were delivered during each session.
Experimental Procedures
For experiments 1–3a and 4, the same group of animals was
used (n= 32), while a different group of animals was used for
experiment 3b (n= 16). For all experiments using drug manipu-
lations (1, 2, 3b), all animals were given a single vehicle injection 1
week prior to the beginning of testing to habituate them to being
injected. Experiments 1, 2, and 3b used a within-group design in
which each rat received all drug or vehicle treatments (IP) in their
particular experiment in a randomly varied order (one treatment
per week). Baseline training sessions (i.e., non-drug) were
conducted 4 days per week.
Experiment 1: Effects of the dopamine D2 antago-
nist haloperidol on PROG/chow feeding choice
performance. To assess the effects of haloperidol, rats were
trained on the PROG/chow procedure described above. On test
days, animals received injections of 0.025, 0.05, 0.1 mg/kg
haloperidol or vehicle, 50 minutes prior to behavioral testing.
Experiment 2: Effects of the adenosine A2A antagonist
MSX-3 on PROG/chow feeding choice performance. To
assess the effects of the adenosine A2A antagonist MSX-3, the same
group of animals was used. The animals were first given 1 week off
from any drug testing, but continued normal baseline training. On
test days, animals received injections of 0.5, 1.0, 2.0 mg/kg MSX-
3 or vehicle, 20 minutes prior to behavioral testing.
Experiment 3a/b: Effects of appetite manipulations on
PROG/chow performance. 3a. Effects of pre-feeding to reduce food
motivation. To assess the effects of pre-feeding, the same group of
animals was again given 1 week of additional baseline training
after experiment 2. The night before testing, animals were taken
off of food restriction and given ad libitum access to lab chow. On
the test day, several hours before behavioral testing, animals were
given ad libitum access to Bio-serv pellets in the home cage.
Performance on the test day was then compared to performance
on the previous baseline day.
3b: Effects of the cannabinoid CB1 inverse agonist and putative appetite
suppressant AM251. For assessment of the effect of AM251, a new
group of animals (n = 16) were trained on the PROG/chow
feeding choice procedure described above. On test days, animals
received injections of 2.0, 4.0, 8.0 mg/kg AM251 or vehicle, 30
minutes prior to testing, once per week, in a randomly varied
order.
Experiment 4: Effects of PROG/chow responding on
pDARPP32-THR34 expression: high vs. low
responders. Following the conclusion of experiment 3, animals
(n = 32) were given 1 week to re-stabilize their baselines. During
the following week, 90 minutes after a baseline training session,
animals were sacrificed and perfused to obtain tissue for
pDARPP32-(Thr34) immunohistochemical analysis. For statistical
analysis, these animals were divided into two groups (high
performers and low performers, determined by a median split of
lever pressing on the day of perfusion).
pDARPP32(Thr34) visualization and quantification
Free floating coronal sections (50 mm) were serially cut using a
cryostat (Weymouth, MA, USA) and rinsed in 0.01 M PBS
(pH 7.4). pDARPP32-(Thr34) immunohistochemistry was con-
ducted according to the methods described previously by Segovia
et al. (2012). The primary anti-pDARPP32-(Thr34) antibody was
used at a concentration of 1:1000 (Santa Cruz Biotechnology,
USA) for 48 h incubation, and the secondary antibody was anti-
rabbit HRP conjugate, envision plus (DAKO, Carpinteria, CA,
USA). The immunohistochemical reaction was developed using
diaminobenzidine (DAB) as the chromagen. The mounted and
cover-slipped sections were examined and photographed using a
Nikon Eclipse E600 (Melville, NY, USA) microscope equipped
with an Insight Spot digital camera (Diagnostic Instruments, Inc).
Images of the regions of interest were magnified at 206 and
captured digitally using SPOT software. Cells that were positively
labeled for pDARPP32-(Thr 34) were quantified with ImageJ
software (v. 1.42, National Institutes of Health sponsored image
analysis program) and a macro written to automate particle
counting within regions of interest (100061000 mm). For each
animal, cell counts were obtained bilaterally from at least three
sections, and counts were averaged across sides and sections. All
cell counting was done by someone who was blind to the
experimental conditions.
Statistical Analysis
For the behavioral pharmacology experiments, number of lever
presses, maximum ratio achieved, active lever time (in seconds)
and chow intake (grams) were analyzed using repeated measures
analysis of variance (ANOVA). Non-orthogonal planned compar-
isons using the ANOVA error term [51] were used to compare
each treatment with the vehicle control. In addition, to provide
another statistical measure of the reciprocal relationship between
lever pressing and chow intake in each experiment, correlations
were performed between number of lever presses and chow intake
data collapsed across all conditions within the experiment. This
measure has been used in previous studies [25,27], and is
potentially influenced by both between subject and treatment-
related variability in lever pressing and chow intake. Thus, in
order to control for the effect of between-subject variability on this
measure, partial correlations that controlled for the vehicle level of
lever pressing also were performed. For experiment 4,
pDARPP32-(Thr34) cell counts were analyzed for differences in
expression between high and low responders (after a median split
of the lever pressing data) for each of 4 regions of interest, and t-
tests were performed to determine significant differences.
Results
Experiment 1: Effects of the DA D2 antagonist haloperidol
Haloperidol significantly decreased the number of lever presses
(F(3,93) = 4.598, p,0.01, see figure 1A). Planned comparisons
revealed that there was a significant difference between 0.1 mg/kg
haloperidol and vehicle (p,0.05). Haloperidol also significantly
decreased maximum ratio achieved (F(3,93) = 8.661, p,0.01,
figure 1B), and the amount of time the lever remained active
Dopamine Effort Progressive Ratio DARPP-32
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(F(3,93) = 6.723, p,0.01, figure 1C); for both measures, planned
comparisons showed a significant difference between vehicle and
0.1 mg/kg haloperidol (p,0.05). Haloperidol produced no
significant effects on chow consumption in the dose range tested
(figure 1D). However, there was a tendency for animals that had
high vehicle rates of responding, and correspondingly low vehicle
levels of chow intake, to show increases in chow intake with
haloperidol; this was marked by a significant correlation between
vehicle number of lever presses and the difference in chow
consumption between vehicle and the highest dose of haloperidol
(r = 0.69, df = 30, p,0.05). Collapsed across all conditions, there
was a significant negative correlation between number of lever
presses and chow consumption (r =20.765, df = 126, p,0.001),
which demonstrated the overall inverse relationship between lever
pressing and chow intake. Moreover, the partial correlation
between lever pressing and chow intake that controlled for
between-subject variability also was statistically significant
(20.557, df = 125, p,0.001), indicating that the inverse relation
between lever pressing and chow intake was evident across
treatments even if one controlled for the between-subject
variability in lever pressing.
Experiment 2: Effects of the adenosine A2A antagonist
MSX-3
MSX-3 significantly increased number of lever presses
(F(3,93) = 4.120, p,0.01, figure 2A), and planned comparisons
showed that both 1.0 and 2.0 mg/kg doses of MSX-3 increased
number of lever presses compared to vehicle (p,0.05). There also
was a significant increase in maximum ratio achieved
(F(3,93) = 8.206, p,0.01, see figure 2B), with the 1.0 and
2.0 mg/kg doses of MSX-3 differing significantly from vehicle
(p,0.05). Furthermore, MSX-3 increased active lever time
(F(3,93) = 3.784, p,0.05, figure 2C), with the 2.0 mg/kg does of
MSX-3 being significantly affected (p,0.05). MSX-3 decreased
chow intake (F(3,93) = 8.017, p,0.01; figure 2D), with a significant
effect at 2.0 mg/kg MSX-3 compared to vehicle (p,0.05). As with
experiment 1, there was a significant negative correlation between
lever presses and chow intake when the data were collapsed across
all conditions (r =20.781, df = 126, p,0.001). In addition, the
partial correlation between lever pressing and chow intake that
controlled for between-subject variability also was statistically
significant (20.597, df = 125, p,0.001). Thus, as with the
haloperidol experiment, the inverse relation between lever
pressing and chow intake was evident across drug treatments
even if one controlled for the between-subject variability in lever
pressing.
Experiment 3: Effects of appetite-related manipulations
on PROG/chow performance: effects of pre-feeding and
the putative appetite suppressant AM251
Experiment 3a studied the effects of pre-feeding on PROG/
chow intake choice performance (figures 3A–D). Compared to the
previous baseline day, pre-feeding the animals prior to the session
produced marked decreases in number of lever presses (t = 2.96,
df = 31, p,0.05), and maximum ratio achieved (t = 3.94, df = 31,
p,0.05), but no significant effect on active lever time. Pre-feeding
significantly decreased chow intake (t = 13.69, df = 31, p,0.01)
compared to previous day baseline performance. There was no
significant overall correlation between number of lever presses and
chow consumption (r = 0.12, df = 62, n.s.), and no significant
partial correlation between lever pressing and chow intake when
we controlled for the between-subject variability in lever pressing
(r = 0.156, df = 61, n.s.). Experiment 3b studied the effects of the
cannabinoid CB1 inverse agonist AM251. AM251 decreased the
number of lever presses (F(3,45) = 3.891, p,0.05, figure 4A), and
the maximum ratio achieved (F(3,45) = 5.811, p,0.05, see
Figure 1. Effects of the dopamine D2 antagonist haloperidol on PROG/chow performance. On measures of lever pressing, mean (6SEM)
total lever presses (A), maximum ratio achieved (B), and active lever time (measured in seconds, C), haloperidol significantly decreased at the highest
dose of 0.1 mg/kg. Chow consumption (mean6SEM, in grams) during test sessions was unaffected by any dose tested (D). (* p,0.05, different from
vehicle)
doi:10.1371/journal.pone.0047934.g001
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figure 4B). Planned comparisons showed that with both measures,
only the highest dose of 8.0 mg/kg AM251 significantly differed
from vehicle (p,0.05). AM251 did not produce any significant
changes in active lever time (figure 4C), but it significantly
decrease chow intake (F(3,45) = 45.634, p,0.01, figure 4D), with
all doses differing from vehicle (p,0.05). There was no significant
overall correlation between number of lever presses and chow
consumption (r =20.05, df = 62, n.s.), and no significant partial
correlation between lever pressing and chow intake when we
controlled for the between-subject variability in lever pressing
(r = 0.234, df = 61, n.s.).
Experiment 4: pDARPP-32(Thr34) Immunohistochemistry
in high and low responders
Performance on the PROG/chow feeding choice task was
highly variable; some rats lever pressed fewer than 100 times and
had high levels of chow intake, while others lever pressed more
than 1000 times and consumed small amounts of chow. This
variability was seen across all the experiments described above,
and in some cases was related to the drug effects seen. For
example, the effects of haloperidol were more marked in rats with
higher control levels of lever pressing. When a median split was
done, and high and low lever pressing was used as a factor in a
264 factorial ANOVA, there was an overall effect of dose
(F[3,90] = 5.071, p,0.05) and importantly, a dose by group
interaction (F[3,90] = 4.189, p,0.05). Although the repeated
measures ANOVA demonstrated that both low and high
responders showed significant decreases in number of lever presses
(low responders: F(3,45) = 2.790, p,0.05; high responders:
F(3,45) = 4.638, p,0.05), analysis of effect sizes showed that the
suppressive effect of haloperidol on number of lever presses was
greater in high responders (eta2 = 0.236) than low responders
(eta2 = 0.157). Similar analyses revealed differences between high
and low responders in the AM251 experiment, with only the high
responders showing a significant drug effect on number of lever
presses. Because of this large variability, the final experiment
investigated potential neurochemical differences between high and
low responders, using pDARPP-32(Thr34) as a marker of signal
transduction activity. To analyze the pDARPP-32(Thr34) expres-
sion data, a median split based upon behavioral performance
during the final test day was performed, yielding two groups: high
responders (n = 16, mean= 812.44, SEM=201.68, range = 205–
2852) and low responders (n = 16, mean= 116.31, SEM=12.81,
range = 54–190). Four regions of interest were selected for analysis:
cingulate cortex CG1/CG2 and accumbens core/shell (Figures 5–
6). There were no differences in pDARPP-32(Thr34) expression
between high and low responders in CG1 (t =20.066, df = 28,
n.s.) or CG2 (t = 0.172, df = 25, n.s.). Nucleus accumbens shell
showed no significant differences in pDARPP-32(Thr34) expres-
sion between high and low responders (t = 1.415, df = 30, n.s.), but
nucleus accumbens core showed a significant difference in
pDARPP-32(Thr34) expression between high and low responders
(t = 2.703, df = 29, p,0.05, figures 5–6).
Discussion
The present studies investigated the effects of several manipu-
lations using a concurrent PROG/chow feeding task. Experiment
1 demonstrated that the DA D2 antagonist haloperidol decreased
number of lever presses, maximum ratio achieved, and active lever
time (i.e., the time the PROG schedule was active). These findings
are consistent with previous studies showing the ability of DA
antagonists or accumbens DA depletions to reduce food-reinforced
lever pressing in animals responding on the concurrent FR5/
choice task [6,25,30], as well as conventional operant schedules,
including various versions of the progressive ratio schedule
[52,53]. Moreover, they are consistent with recent research
Figure 2. Effects of the adenosine A2A antagonist MSX-3 on PROG/chow performance. On measures of lever pressing, mean (6SEM) total
lever presses (A) and maximum ratio achieved (B) were both significantly increased at doses of 1.0 and 2.0 mg/kg while active lever time (measured in
seconds, C) was only increased at a dose of 2.0 mg/kg. Chow consumption (mean6SEM, in grams) during test sessions was significantly decreased at
the dose of 2.0 mg/kg (D). (* p,0.05, different from vehicle)
doi:10.1371/journal.pone.0047934.g002
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showing that the increased DA transmission resulting from DA
transporter knockdown enhanced progressive ratio performance,
including conditions in which a PROG schedule reinforced by
sucrose was available in the home cage and non-deprived animals
also had their homecage food available [13]. Despite producing
clear reductions in measures of operant responding, haloperidol
did not decrease chow intake, which indicates that primary food
motivation was intact in haloperidol-treated rats. Moreover,
Figure 3. Effects of prefeeding on PROG/chow performance. On measures of lever pressing, mean (+SEM) total lever presses (A), maximum
ratio achieved (B), and active lever time (measured in seconds, C) were all significantly decreased with prefeeding. Chow consumption (mean+SEM, in
grams) during test sessions was significantly decreased by prefeeding animals prior to the test session (D). (* p,0.05, different from vehicle)
doi:10.1371/journal.pone.0047934.g003
Figure 4. Effects of the cannabinoid CB1 inverse agonist AM251 on PROG/chow performance. On measures of lever pressing, mean
(6SEM) total lever presses (A) and maximum ratio achieved (B) were significantly decreased at 8.0 mg/kg while active lever time (measured in
seconds, C) was unaffected at any dose tested. Chow consumption (mean6SEM, in grams) during test sessions was significantly decreased at 2.0, 4.0
and 8.0 mg/kg doses (D). (* p,0.05, different from vehicle)
doi:10.1371/journal.pone.0047934.g004
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previous studies have shown that 0.1 mg/kg haloperidol does not
change preference for these specific high carbohydrate food pellets
relative to chow, or reduce total intake of either food type in free-
feeding tests [6,54]. In fact, there was a slight tendency for some
rats to show increased chow intake after haloperidol treatment,
which was marked by the significant correlation between vehicle
lever pressing and the difference in chow intake between vehicle
and the highest dose of haloperidol. In other words, animals that
were high lever press responders under the vehicle condition, and
therefore had correspondingly low levels of chow intake, showed
greater increases in chow consumption on haloperidol than low
responders did. In fact, the 4 rats with the highest level of lever
pressing showed very substantial increases in chow intake after
haloperidol injection (i.e., increases of 3–6 grams relative to
vehicle). Nevertheless, unlike the previous experiments using the
FR5/chow choice task [6,25,30], haloperidol did not produce an
overall significant increase in chow intake. One possible explana-
tion for this pattern is the different levels of chow intake with the
two procedures. With the FR5/chow choice procedure, baseline
or control levels of lever pressing are relatively high, while chow
intake is relatively low (i.e., 1–2 grams), making it possible to
observe an increase in chow intake with administration of a DA
antagonist. In contrast, baseline or control levels of chow intake
are much higher with the PROG/chow choice procedure (i.e., 7–8
grams), and are near ceiling levels of chow intake for a 30 minute
period without water being available. For example, Randall et al.
[50] demonstrated that food-restricted rats in a free feeding study
consume approximately 8 grams of chow in a 30-minute period.
Thus, with the PROG/chow choice procedure, it is difficult to
observe drug-induced increases in chow intake in animals that are
Figure 5. pDARPP-32(Thr34) immunocytochemistry. (A and B) Atlas plates (modified from Paxinos and Watson [68] with regions of interest
denoted by squares. (C) High magnification photomicrograph of pDARPP-32(Thr34) immunoreactive cells at 406magnification. Several pDARPP-
32(Thr34) positive cells are shown, including a darkly staining cell, with clear soma and dendritic processes (arrow) (D) Mean (6SEM) number of
pDARPP-32(Thr34) positive cells counted in each region of interest in high performers and low performers. There were significantly more pDARPP-
32(Thr34) positive cells counted in the nucleus accumbens core of high performers compared to low performers. (* p,0.05)
doi:10.1371/journal.pone.0047934.g005
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already eating chow at maximal or near maximal levels.
Nevertheless, compared to the FR5/chow choice procedure, the
PROG/chow choice task is better suited for observing large
reductions in chow intake due to appetite-related manipulations
such as pre-feeding or appetite suppressant drugs (see discussion
below).
The adenosine A2A antagonist MSX-3 produced effects that
were opposite to those of haloperidol; MSX-3 increased number of
lever presses and maximum ratio achieved, and also increased the
amount of time that animals kept the lever active during the
session. This is consistent with previous work showing that
adenosine A2A antagonists have stimulant-like properties. For
example, the adenosine A2A antagonists MSX-3 and istradefylline
increased lever pressing on a fixed interval 4-minute schedule,
which generates a relatively low baseline rate of responding [40].
In addition, the PROG/chow feeding choice procedure allowed
for parallel assessment of food intake, and MSX-3 decreased chow
consumption at the highest dose. Interestingly, although MSX-3
and haloperidol produced opposite effects on measures of PROG
lever pressing and chow intake, in both experiments, the reciprocal
relation between lever pressing and chow intake was preserved, as
indicated by the high negative correlations between lever pressing
and chow intake across all treatments (20.76 and 20.78).
Significant negative partial correlations also were observed in
the haloperidol and MSX-3 experiments when partial correlations
were used to control for between-subject variability in lever
pressing. This inverse correlation between lever pressing and chow
intake has been reported in previous experiments studying the
effects of DA antagonists or depletions on FR5/chow feeding
choice performance [25,27,30].
Experiment 3 was conducted to determine the effect of appetite-
related manipulations on PROG/chow feeding choice perfor-
mance, in order to provide a contrast with the effects of
haloperidol. Two different appetite manipulations were employed:
pre-feeding, and administration of a cannabinoid CB1 receptor
antagonist/inverse agonist. Pre-feeding animals prior to their test
session, which was used to reduce food motivation and thereby
devalue the food reinforcement [15,54], produced marked
decreases in number of lever presses and highest ratio achieved.
But, unlike the effects of haloperidol, pre-feeding also substantially
reduced chow consumption. In experiment 3b, the CB1 receptor
antagonist/inverse agonist AM251 was assessed. CB1 antagonists/
inverse agonists are putative appetite suppressant drugs that have
been shown to decrease food intake in animals [30,49,50,55] and
humans [56]. Moreover, stimulation of CB1 receptors in nucleus
accumbens shell increased hedonic taste reactivity for intraoral
sucrose [57]. On the PROG/chow feeding choice task, AM251
decreased number of lever presses, maximum ratio achieved, and
chow consumption. Thus, the pattern of effects on lever pressing
and chow intake produced by pre-feeding and AM251 differed
markedly from those produced by haloperidol. Moreover, while
there was a high inverse correlation between lever pressing and
chow intake in the haloperidol experiment, there were no
significant correlations or partial correlations between these
measures in the pre-feeding and AM251 experiments. This
analysis shows that the inverse relation between lever pressing
and chow intake, which is evident under baseline conditions and
also throughout the haloperidol experiment, is not shown when
primary food motivation is reduced by pre-feeding or drugs,
because appetite-suppressant manipulations decrease both food
reinforced lever pressing and chow consumption [25,30]. There
are a number of factors that can influence progressive ratio
performance [58], and rather than yielding a simple measure of
‘‘reward’’, progressive ratio breakpoints represent the outcome of a
cost/benefit analysis related partially to characteristics of the
reinforcer itself, but also the work-related response costs and time
constraints imposed by the ratio schedule [2]. Indeed, previous
work has demonstrated that progressive ratio break points are
sensitive to work-related factors such as the height of the lever
[59]. Taken together, experiments 1–3 demonstrate that it is
exceedingly unlikely that haloperidol is decreasing PROG lever
pressing because of a reduction in primary food motivation,
appetite, or the unconditioned reinforcing properties of food.
Clearly, in the absence of parallel measures of food intake, or taste
reactivity [57,60], progressive ratio break points should not be
used as markers of food ‘‘reward’’, or ‘‘hedonic’’ reactivity to food
[61]. Rather, they provide a measure of how much work the
organism will do in order to gain access to a reinforcing stimulus
[2,61,62].
An important aspect of the PROG/choice procedure is that
performance is characterized by substantial individual variability.
While some rats lever pressed relatively little and had high levels of
chow intake, others lever pressed much more and ate relatively
little chow. Experiment 4 employed pDARPP-32-(Thr34) immu-
nohistochemistry to determine if there were neurochemical
differences between high responders and low responders. The
entire group of animals was divided in two by a median split based
upon numbers of lever presses, and pDARPP-32(Thr34) expres-
sion was determined. High responders did not differ from low
Figure 6. Photomicrographs of pDARPP-32(Thr34) staining in
each region of interest, showing representative low performer
(left column) and high performer (right column). All images were
taken at 106magnification.
doi:10.1371/journal.pone.0047934.g006
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responders in terms of pDARPP-32(Thr34) expression in CG1 or
CG2 regions of anterior cingulate cortex. In the accumbens shell,
there was a slight tendency for high responders to show increased
pDARPP-32 expression, but this was not statistically significant.
However, high responders did show significantly greater
pDARPP-32(Thr34) expression in accumbens core than low
responders. pDARPP-32(Thr34) immunoreactivity was used to
provide a marker of signal transduction activity, and evidence
indicates that DA acting through the D1 receptor and related G
proteins (Gs/Golf) activates adenylate cyclase activity, thereby
stimulating PKA-mediated phosphorylation of DARPP-32 at the
Thr34 site [45–48]. DARPP-32 expression has been used to study
drug effects [47,48], and a few studies have focused on changes in
DARPP-32 immunoreactivity associated with behavioral manip-
ulations. Danielli et al. [63] demonstrated that pDARPP-
32(Thr34) showed increased expression in nucleus accumbens
shell after the first exposure to a novel food. Recently, Segovia et
al. [44] reported that pDARPP-32(Thr34) expression in accum-
bens shell and core was increased in animals undergoing FR5
operant training. Although several neurochemical factors can
influence pDARPP-32(Thr34) production [48], it is reasonable to
suggest that the higher level of pDARPP-32(Thr34) expression in
high responders relative to low responders could reflect greater
DA release in the animals working harder on the lever pressing
component of the task [44,64]. If so, this could indicate that
individual differences in work output are related to individual
differences in DA transmission in striatal areas, as recently shown
in a human imaging study [65]. Furthermore, these observations
of individual variability in exertion of physical effort are consistent
with recent studies of individual variability in cognitive effort
across subjects (i.e., ‘‘workers’’ vs. ‘‘slackers’’) [66].
Conclusions
In summary, the DA antagonist haloperidol reduced the
number of lever presses and highest ratio achieved but did not
suppress chow intake. In contrast, the adenosine A2A antagonist
MSX-3 increased lever presses and highest ratio achieved, but
decreased chow consumption. Pre-feeding and administration of
the cannabinoid CB1 antagonist/inverse agonist AM251 de-
creased lever presses, highest ratio achieved, and chow intake.
Including the option of having chow concurrently available allows
one to conclude that the effects of DA antagonism differed greatly
from those produced by pre-feeding or decreases in CB1
transmission, despite the fact that all three manipulations
decreased lever pressing. Thus, haloperidol is not reducing PROG
responding because of a general reduction in primary food
motivation or the valuation of food reinforcement. Instead, the
present data are consistent with the hypothesis that haloperidol left
aspects of food motivation intact, but reduced the tendency to
work for food reinforcement. Furthermore, DA-related signal
transduction activity (pDARPP-32(Thr34) expression) was greater
in high responders (i.e., rats with high lever pressing output)
compared to low responders, indicating that accumbens core
signal transduction activity is related to individual differences in
work output. Future studies should compare the effects of DA D1
and D2 antagonists, and should determine if adenosine A2A
antagonism is capable of reversing the effects of DA antagonism.
Studies comparing cannabinoid CB1 inverse agonists with neutral
antagonists (e.g. 50, 30) would be useful for further exploration of
the role of CB1 receptor signaling in performance on this
procedure. Finally, additional neurochemical measures should be
investigated for their possible relation to lever pressing output on
this task, including microdialysis studies of DA release [64], and
other markers of signal transduction activity (e.g. c-Fos, pDARPP-
32(Thr75)) in different striatal cell types (e.g. encephalin or
substance P positive neurons; [44]). These studies are important
for understanding activational aspects of motivation, and may
contribute to our understanding of the neural basis of effort-related
motivational impairments (e.g. anergia, psychomotor retardation,
fatigue) in depression and other disorders [1,2,67].
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